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The field of respiratory medicine has evolved considerably in the last 10 to 20 years.
Many new treatments have been developed during this time through basic and translational research. Clinical trials have helped to guide new treatment approaches for patients with pulmonary hypertension, lung cancer, critical illness, sleep apnea, asthma, COPD, pulmonary fibrosis and other conditions (1) (2) (3) (4) . A robust pipeline of young investigators and scholarly clinicians will be required for the major advances to continue.
The American Thoracic Society (ATS) and Chinese Thoracic Society (CTS) are both large professional societies committed to attracting and retaining top candidates in our field (5-7). In the U.S., pulmonary disease and critical care medicine have been We are optimistic about the future of the field of pulmonary, critical care and sleep medicine among our Chinese colleagues. The times are exciting given the major recent progress that has occurred and the transformative advances that are likely to occur in the coming years. As the ATS and CTS strive to attract the best and brightest into our field, they also play a pivotal role in encouraging all of us to maintain scholarly and 7
